[HTML][HTML] Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials
Cervical cancer constitutes a significant health burden for women globally. While most
patients with early-stage disease can be cured with radical surgery or chemoradiotherapy …
patients with early-stage disease can be cured with radical surgery or chemoradiotherapy …
Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data
Z Song, K Zou, L Zou - Frontiers in oncology, 2022 - frontiersin.org
Immunotherapy has shown great promise in the field of oncology, and recent clinical trials
have illustrated that immune checkpoint blockade (ICB) is safe and effective at treating a …
have illustrated that immune checkpoint blockade (ICB) is safe and effective at treating a …
The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry
Background Small cell carcinoma of the cervix is a rare but poor prognosis pathological type
of cervical cancer, for which advice in clinical guidelines is unspecific. We therefore aimed to …
of cervical cancer, for which advice in clinical guidelines is unspecific. We therefore aimed to …
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical …
M Frumovitz, GB Chisholm, A Jhingran… - American journal of …, 2023 - Elsevier
Background Recurrent high-grade neuroendocrine cervical cancer has a very poor
prognosis and limited active treatment options. Objective This study aimed to evaluate the …
prognosis and limited active treatment options. Objective This study aimed to evaluate the …
Prognostic model for survival in patients with neuroendocrine carcinomas of the cervix: SEER database analysis and a single-center retrospective study
C Yu, X Wu, S Zhang, L Zhang, H Zhang, H Yang… - Plos one, 2024 - journals.plos.org
Objective Neuroendocrine carcinoma of the cervix (NECC) is extremely rare in clinical
practice. This study aimed to methodologically analyze the clinicopathological factors …
practice. This study aimed to methodologically analyze the clinicopathological factors …
Population-Based Survival Analysis of Stage IVB Small-Cell Neuroendocrine Carcinoma in Comparison to Major Histological Subtypes of Cervical Cancer
S Mabuchi, N Komura, T Sasano, M Sakata… - Current …, 2023 - mdpi.com
The aim of the current study is to investigate the survival outcome of stage IVB SCNEC of the
uterine cervix in comparison to major histological subtypes of cervical cancer. A population …
uterine cervix in comparison to major histological subtypes of cervical cancer. A population …
Competing risk nomogram and risk classification system for evaluating overall and cancer-specific survival in neuroendocrine carcinoma of the cervix: a population …
J Liu, Y Lyu, Y He, J Ge, W Zou, S Liu, H Yang… - Journal of …, 2024 - Springer
Objective Neuroendocrine carcinoma of the cervix (NECC) is a rare malignancy with poor
clinical prognosis due to limited therapeutic options. This study aimed to establish a risk …
clinical prognosis due to limited therapeutic options. This study aimed to establish a risk …
[HTML][HTML] Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
M Towner, K Novak, YK Chae, D Matei - Gynecologic Oncology Reports, 2022 - Elsevier
Neuroendocrine carcinoma of the cervix is a rare subtype of cervical cancer with a poor
prognosis. Primary treatment of this disease involves a combination of surgery …
prognosis. Primary treatment of this disease involves a combination of surgery …
[HTML][HTML] Advanced stage (FIGO IVB) neuroendocrine cervical carcinoma presenter
G Salvo, M Frumovitz, P Ramalingam… - International journal of …, 2022 - ncbi.nlm.nih.gov
A 41-year-old G5P3 woman presented with a six-month history of intermittent vaginal
spotting. Two months before consultation she began having lower abdominal and pelvic …
spotting. Two months before consultation she began having lower abdominal and pelvic …
Neuroendocrine cervical cancer: Have we made any steps forward in its management?
A Mandic, T Maksimovic, GS Nadj, S Maricic… - European Journal of …, 2024 - Elsevier
Introduction Neuroendocrine tumors (NEC) were first described by Albores-Saavedra in
1972 and these tumors account for only 0.9% to 1.5% of all invasive cervical cancers. 1, 2 …
1972 and these tumors account for only 0.9% to 1.5% of all invasive cervical cancers. 1, 2 …